Journal of the National Cancer Institute Advance Access originally published online on December 30, 2008
JNCI Journal of the National Cancer Institute 2009 101(1):11-13; doi:10.1093/jnci/djn483
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© Oxford University Press 2008.
NEWS |
Biomarker Studies Abound for Early Detection of Lung Cancer
| The first 150 words of the full text of this article appear below. |
A recent study has identified 26 genes frequently mutated in lung cancer, doubling the number of genes implicated in this disease. Published last month in Nature, the study found that these genes are mutated at a high frequency in adenocarcinoma of the lung, the most common form of non–small-cell lung cancer.
These genes therefore may also be involved in the development of the disease, said one of the lead investigators, Matthew Meyerson, M.D., Ph.D., associate professor of pathology at Harvard Medical School in Boston. "Finding a number of protein kinase and tumor suppressor gene mutations involved in this disease has potential implications not only in treatment but also for diagnosis," Meyerson said.
The study, part of the National Institutes of Health's Tumor Sequencing Project, is one of many efforts focused on biomarkers in lung cancer, many driven by the pressing need to find a way to detect the disease
Genomics and Proteomics
Gauging Immune Reaction
Obstacles and Challenges